|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM337504377 |
| 003 |
DE-627 |
| 005 |
20231225234547.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2022 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2022.108960
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1124.xml
|
| 035 |
|
|
|a (DE-627)NLM337504377
|
| 035 |
|
|
|a (NLM)35218965
|
| 035 |
|
|
|a (PII)S1521-6616(22)00040-7
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Shang, Wenli
|e verfasserin
|4 aut
|
| 245 |
1 |
4 |
|a The safety of long-term use of inhaled corticosteroids in patients with asthma
|b A systematic review and meta-analysis
|
| 264 |
|
1 |
|c 2022
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 06.05.2022
|
| 500 |
|
|
|a Date Revised 06.05.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2022 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a PURPOSE: This systematic review and meta-analysis was performed to determine the safety of long-term use of ICS in patients with asthma
|
| 520 |
|
|
|a METHODS: A systematic search was made of PubMed, Embase, Web of Science, Cochrane Library, and clinicaltrials.gov, without language restrictions. Randomized controlled trials (RCTs) on treatment of asthma with ICS, compared with non-ICS treatment (placebo or other active drugs), were reviewed
|
| 520 |
|
|
|a RESULTS: Eighty-six RCTs (enrolling 51,538 participants) met the inclusion criteria. Oral or oropharyngeal candidiasis (RR 2.58, 95% CI 2.00 to 3.33), and dysphonia/hoarseness (RR 1.56, 95% CI 1.31 to 1.85) were less frequent in the control group. There was no statistically significant difference in the risk of upper respiratory tract infection, lower respiratory tract infection, influenza, decline in bone mineral density, and fractures between the two groups
|
| 520 |
|
|
|a CONCLUSION: In addition to the mild local adverse events, the long-term use of ICS was safe in patients with asthma
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Meta-Analysis
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a Systematic Review
|
| 650 |
|
4 |
|a Adverse events
|
| 650 |
|
4 |
|a Asthma
|
| 650 |
|
4 |
|a Inhaled corticosteroids
|
| 650 |
|
4 |
|a meta-analysis
|
| 650 |
|
7 |
|a Adrenal Cortex Hormones
|2 NLM
|
| 650 |
|
7 |
|a Anti-Asthmatic Agents
|2 NLM
|
| 700 |
1 |
|
|a Wang, Guizuo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Yan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Han, Dong
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 236(2022) vom: 15. März, Seite 108960
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:236
|g year:2022
|g day:15
|g month:03
|g pages:108960
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2022.108960
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 236
|j 2022
|b 15
|c 03
|h 108960
|